Daclizumab

Zinbryta

150MG/ML InjectionUnited StatesWithdrawnAuthorised 26 May 2017

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Documents

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Daclizumab

Zinbryta

150MG/ML InjectionUnited StatesWithdrawnAuthorised 26 May 2017

Open in the registerAsk Osler about it

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Documents

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

The official texts, at the regulator.

Register entryFDA

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

U.S. Food and Drug Administration

FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.

Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions · Added 11 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Daclizumab
Strength: 150MG/ML
Dosage form: Injection
Route: Subcutaneous
Register: United States (FDA)
Status: Withdrawn
Status in the register: Voluntarily Revoked / Disc
Authorised: 26 May 2017
Registration: BLA 761029
Marketing authorisation holder: Biogen Inc.
Procedure: 351(a)
Supply: Disc